Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 5CNS 4Breast 2Tumor-Agnostic 1Sarcoma 1Genitourinary 1Endocrine 1

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Triiodothyronine × Breast × Clear all
NCT03787303 2022-05-13

B-TREUH

Aultman Health Foundation

Phase 2 Terminated
7 enrolled 14 charts
Breast

Breast Neoplasms

NCT01360177 2016-07-20

Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers

Stanford University

Phase NA Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡